Stem Cell Transplant for Hematological Malignancy
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute
About this trial
This is an interventional treatment trial for Leukemia, Myeloid, Chronic focused on measuring stem cell transplant, chronic leukemia, acute leukemia, irradiation, chemotherapy
Eligibility Criteria
Inclusion Criteria: Donor will be <75 years of age and in good health. Recipients will be < or = 55 years, will have normal organ function (excluding bone marrow) and will have a Karnofsky activity assessment > or = 90%. Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or mismatched related or unrelated (if < 35 years old) at a single HLA A, B, DRB1 locus. Recipients will be eligible in one of the following disease categories Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine kinase inhibitors. Acute myelocytic leukemia in first or greater remission, or first, second or third relapse. Acute lymphocytic leukemia in the 2nd or greater bone marrow remission. High risk children will be transplanted in first remission if they meet criteria Myelodysplastic syndrome. Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia (CMML)) Juvenile myelomonocytic leukemia Chronic lymphocytic leukemia Advanced non-Hodgkin's (NHL). Advanced Hodgkin's disease beyond PR2 (> CR3, > PR3). Multiple Myeloma after initial therapy. Donors and recipients signed informed consent Exclusion Criteria donors and recipients should meet the following test criteria. required for donors: anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-priming. CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed) required for recipients: anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-transplant.
Sites / Locations
- Masonic Cancer Center, University of Minnesota
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
PBSC: No TBI
Marrow : No TBI
UCB : No TBI
UCB : No TBI/Bu/Cy/ATG
PBSC
Marrow
UCB
Co-Enroll From MT0403
Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)